Expertise in
1
conditions

Dr. Nadim Nimeh

Hematology
Cancer Centers Of Southwest Oklahoma LLC
104 NW 31st St, 
Lawton, OK 
Expertise in
1
conditions
Cancer Centers Of Southwest Oklahoma LLC
104 NW 31st St, 
Lawton, OK 

Overview

Nadim Nimeh is a Hematologist practicing medicine in Lawton, Oklahoma.

Dr. Nimeh is highly rated in 1 condition, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Breast Cancer, Lung Cancer, and Paget Disease of the Breast.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 9 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in OK

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Cancer Centers of Southwest Oklahoma LLC
104 NW 31st St, Lawton, OK 73505

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 01, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: August 20, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

2 Total Publications

Clinical cancer trials in a rural community cancer center in Southwest Oklahoma from 2000-2009.
Clinical cancer trials in a rural community cancer center in Southwest Oklahoma from 2000-2009.
Journal: The Journal of the Oklahoma State Medical Association
Published: March 20, 2013
Similar Doctors
Expertise in
33
conditions
Dr. Manal Robin
Hematology
Expertise in
33
conditions
Dr. Manal Robin
Hematology
Referral may be required

Cancer Centers Of Southwest Oklahoma LLC

104 NW 31st St, 
Lawton, OK 
 (0.1 miles away)
580-536-2121
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Manal Robin is a Hematologist practicing medicine in Lawton, Oklahoma. Dr. Robin is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Lung Cancer, and Pleuropulmonary Blastoma.

Expertise in
36
conditions
Dr. Sripriya Santhanam
Hematology | Oncology
Expertise in
36
conditions
Dr. Sripriya Santhanam
Hematology | Oncology
Referral may be required

Cancer Centers Of Southwest Oklahoma, LLC

104 Nw 31st St, 
Lawton, OK 
 (0.1 miles away)
580-536-2121
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sripriya Santhanam is a Hematologist and an Oncologist practicing medicine in Lawton, Oklahoma. Dr. Santhanam is highly rated in 36 conditions, according to our data. Her clinical expertise encompasses Myelodysplastic Syndrome (MDS), Lung Cancer, Pleuropulmonary Blastoma, and Inflammatory Breast Cancer.

Expertise in
62
conditions
Expertise in
62
conditions
Referral may be required

Texas Oncology Pharmacy-Wichita Falls

5400 Kell Blvd, 
Wichita Falls, TX 
 (51.7 miles away)
940-691-8271
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Praveen Reddy is a Hematologist practicing medicine in Wichita Falls, Texas. Dr. Reddy is highly rated in 62 conditions, according to our data. His clinical expertise encompasses Iron Deficiency Anemia, Paget Disease of the Breast, Familial Colorectal Cancer, and Pleuropulmonary Blastoma.

Frequently Asked Questions about Dr. Nadim Nimeh

How do I make an appointment with Dr. Nadim Nimeh?

You can book an appointment with Dr. Nadim Nimeh by calling their office at 580-536-2121. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nadim Nimeh a top-rated expert for Pleuropulmonary Blastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nadim Nimeh is classified as an Advanced expert for Pleuropulmonary Blastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nadim Nimeh specialize in?

While Dr. Nadim Nimeh is a Hematology, they have specific expertise in Pleuropulmonary Blastoma, Breast Cancer, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Nadim Nimeh participate in research or clinical trials?

Yes. Dr. Nadim Nimeh has published 2 articles and abstracts on conditions like Pleuropulmonary Blastoma. You can view a list of Dr. Nadim Nimeh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nadim Nimeh accept my insurance?

Dr. Nadim Nimeh accepts most major insurance plans, including Blue Cross Blue Shield and UnitedHealthcare. We recommend calling the office directly at 580-536-2121 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nimeh's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile